Results 1 to 10 of about 41,710 (302)

Dipeptidyl Peptidase-4 Inhibitor-Associated Bullous Pemphigoid [PDF]

Frontiers in Immunology, 2019
Bullous pemphigoid (BP) is an organ-specific autoantibody-mediated blistering skin disease that mainly affects the elderly. Typical clinical features include the widespread blisters, often preceded by and/or associated with itchy urticarial or eczema ...
Kaisa Tasanen, Outi Varpuluoma, Wataru Nishie   +2 more
doaj   +4 more sources

Cardioprotective effects of sodium glucose cotransporter 2 inhibitor versus dipeptidyl peptidase 4 inhibitor in type 2 diabetes: A meta-analysis of comparative safety and efficacy [PDF]

SAGE Open Medicine
Background: Sodium glucose cotransporter 2 inhibitors are recommended for the treatment of heart failure due to their cardioprotective effects, despite primarily being used as antidiabetic medications. However, the comparative profile of two antidiabetic
Abhigan Babu Shrestha, Anupam Halder, Kripa Rajak, Saroj Kumar Jha, Ramesh Lamichhane, Arefin Naher Oishee, Nayanika Tummala Chowdary, Pashupati Pokharel, Sajina Shrestha, Lukash Adhikari, Bikash Adhikari, Aman Rajak, Jalal Haider Khan, Nischal Mainali   +13 more
doaj   +2 more sources

Ocular cicatricial pemphigoid following Dipeptidyl Peptidase-4 inhibitor use: A case report [PDF]

American Journal of Ophthalmology Case Reports, 2023
Purpose: To report a rare Ocular Cicatricial Pemphigoid (OCP) case in a patient taking a Dipeptidyl Peptidase-4 Inhibitor (DPP-4 inhibitor), a medication used for the management of type 2 diabetes, for at least six years. Observations: A 64-year-old male
Akifumi Matsumoto, Hideki Fukuoka, Akiko Yoneda, Norihiko Yokoi, Chie Sotozono   +4 more
doaj   +2 more sources

Association of dipeptidyl peptidase‐4 inhibitor use and risk of pancreatic cancer in individuals with diabetes in Japan [PDF]

Journal of Diabetes Investigation, 2023
Aims/Introduction This study was designed and carried out to investigate the association of dipeptidyl peptidase‐4 inhibitor (DPP‐4i) use with pancreatic cancer (PC) in individuals with diabetes in Japan.
Sodai Kubota, Takuya Haraguchi, Hitoshi Kuwata, Yusuke Seino, Kenta Murotani, Takumi Tajima, Gen Terashima, Makiko Kaneko, Yoshihiro Takahashi, Ken Takao, Takehiro Kato, Kenichiro Shide, Saeko Imai, Atsushi Suzuki, Yasuo Terauchi, Yuichiro Yamada, Yutaka Seino, Daisuke Yabe   +17 more
doaj   +2 more sources

Neuroprotective effects of dipeptidyl peptidase 4 inhibitor on Alzheimer’s disease: a narrative review [PDF]

Frontiers in Pharmacology
Insulin resistance in brain and amyloidogenesis are principal pathological features of diabetes-related cognitive decline and development of Alzheimer’s disease (AD).
Xin Jiang, Ji Li, Xiaohui Yao, Hao Ding, Aihong Gu, Zhen Zhou   +5 more
doaj   +2 more sources

Severe edema and blood blisters of the lower extremities caused by sitagliptin, a dipeptidyl peptidase‐4 inhibitor [PDF]

Journal of General and Family Medicine, 2022
Hiroki Maita, Tadashi Kobayashi, Takashi Akimoto, Hiroshi Osawa, Hiroyuki Kato   +4 more
doaj   +2 more sources

Trelagliptin (SYR-472, Zafatek), Novel Once-Weekly Treatment for Type 2 Diabetes, Inhibits Dipeptidyl Peptidase-4 (DPP-4) via a Non-Covalent Mechanism. [PDF]

PLoS ONE, 2016
Trelagliptin (SYR-472), a novel dipeptidyl peptidase-4 inhibitor, shows sustained efficacy by once-weekly dosing in type 2 diabetes patients. In this study, we characterized in vitro properties of trelagliptin, which exhibited approximately 4- and 12 ...
Charles E Grimshaw, Andy Jennings, Ruhi Kamran, Hikaru Ueno, Nobuhiro Nishigaki, Takuo Kosaka, Akiyoshi Tani, Hiroki Sano, Yoshinobu Kinugawa, Emiko Koumura, Lihong Shi, Koji Takeuchi   +11 more
doaj   +1 more source

Predictive Clinical Parameters and Glycemic Efficacy of Vildagliptin Treatment in Korean Subjects with Type 2 Diabetes [PDF]

Diabetes & Metabolism Journal, 2013
BackgroundThe aims of this study are to investigate the glycemic efficacy and predictive parameters of vildagliptin therapy in Korean subjects with type 2 diabetes.MethodsIn this retrospective study, we retrieved data for subjects who were on twice-daily
Jin-Sun Chang, Juyoung Shin, Hun-Sung Kim, Kyung-Hee Kim, Jeong-Ah Shin, Kun-Ho Yoon, Bong-Yun Cha, Ho-Young Son, Jae-Hyoung Cho   +8 more
doaj   +1 more source

Dynamics of total volume of pancreatic α‐ and β ‐cells under the influence sulfonylureas and their combination with dipeptidyl peptidase‐4 inhibitors

Endocrinology, Diabetes & Metabolism, 2021
Objective Sulfonylureas and dipeptidyl peptidase‐4 inhibitors have a multidirectional effect on pancreatic cells. We aimed to evaluate the effects of these drugs on β‐ and α‐cells in rats aged 12 months with type 2 diabetes mellitus when administered in ...
Tuchina Taisiia Pavlovna, Skotnikova Kseniia Petrovna, Vtorushina Anna Anatolievna, Uskov Ivan Sergeyevich, Rogoza Olga Vladimirovna, Grozov Roman Viktorovich, Babenko Alina Yurievna, Galagudza Mikhail Mikhailovich   +7 more
doaj   +1 more source

Late Onset Dipeptidyl Peptidase -4 Inhibitor Associated Seronegative Rheumatoid Arthritis

Journal of Nepal Health Research Council, 2021
Drug-induced arthritis is not an uncommon scenario. DPP-4 inhibitors could potentially cause adverse-events mediated by cytokine-induced inflammation leading to arthritis. The activity of the DPP-4 enzyme could be inversely related to the development of
Binit Vaidya, Bhojraj Adhikari, Manisha Bhochhibhoya, Shweta Nakarmi   +3 more
doaj   +1 more source